BLISS GVS PHARMA share price has zoomed 7% and is presently trading at Rs 129.0.
Meanwhile, the BSE HEALTHCARE index is at 42,466.2 (up 0.2%).
Among the top gainers in the BSE HEALTHCARE index today are FORTIS HEALTHCARE (up 3.4%) and KIMS (up 3.1%).
SUN PHARMA ADV. RES. (down 3.0%) and GSK Pharma (down 2.7%) are among the top losers today.
Over the last one year, BLISS GVS PHARMA has moved down from Rs 138.8 to Rs 129.0, registering a loss of Rs 9.8 (down 7.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 29,583.1 to 42,466.2, registering a gain of 43.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 159.9%), SUVEN PHARMACEUTICALS (up 114.6%) and FORTIS HEALTHCARE (up 88.5%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 77,162.3 (down 0.5%).
The top losers among the BSE Sensex today are MUNDRA PORT & SEZ (down 13.6%) and NTPC (down 2.7%). The most traded stocks in the BSE Sensex are Tata Steel and MUNDRA PORT & SEZ.
In the meantime, NSE Nifty is at 23,349.4 (down 0.7%). Adani Enterprises and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,655.2 to 77,162.3, registering a gain of 11,507.1 points (up 17.5%).
BLISS GVS PHARMA net profit fell 40.3% YoY to Rs 257 million for the quarter ended September 2024, compared to a profit of Rs 430 million a year ago. Net sales rose 2.7% to Rs 2,177 million during the period as against Rs 2,119 million in July-September 2023.
For the year ended March 2024, BLISS GVS PHARMA reported 6.3% increase in net profit to Rs 816 million compared to net profit of Rs 767 million during FY23. Revenue of the company grew 2.5% to Rs 7,702 million during FY24.
The current Price to earnings ratio of BLISS GVS PHARMA, based on rolling 12 month earnings, stands at 18.9.
Equitymaster requests your view! Post a comment on "BLISS GVS PHARMA Gains 7%; BSE HEALTHCARE Index Up 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!